News
The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.
The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.
After Decades Without Progress in Glioblastoma, Diakonos Stirs Up Interest in Dendritic Cell Vaccine
The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback